Axillary temperature# °C | 40.5 | 39.0 | 38.3 | Apyrexia | Apyrexia | Apyrexia |
Respiratory rate breaths·min−1 | 60 | 55 | 52 | 45 | 25 | 24 |
Sp,O2¶ % | 85 | 88 | 85 | 90 | 95 | 98 |
Heart rate beats·min−1 | 135 | 139 | 140 | 110 | 82 | 76 |
Blood pressure mmHg | 90/60 | 93/61 | 88/58 | 91/62 | 95/65 | 90/60 |
Chest radiography | Multiple “ground- glass” infiltrates | NE | “Ground-glass” opacifications | NE | Significantly improved | NE |
Chest CT scan | NE | Bilateral infiltrates, with “ground-glass” opacifications | NE | NE | NE | NE |
White blood cell count cells·μL−1 | 10100 | NE | 11860 | 11280 | 4900 | 6790 |
Neutrophils % | 79 | NE | 82 | 84 | 41 | 60 |
CRP mg·dL−1 | 14.2 | 7.1 | 7.1 | 3.9 | 0.8 | <0.3 |
ESR mm first hour | 53 | NE | 48 | NE | NE | 11 |
Bacterial findings | M. pneumoniae DNA in nasopharyngeal swab | M. pneumoniae DNA in nasopharyngeal swab | M. pneumoniae DNA in nasopharyngeal swab and BAL | M. pneumoniae DNA in nasopharyngeal swab | M. pneumoniae DNA in nasopharyngeal swab | Negative |
Genotype | Variant 2a | Variant 2a | Variant 2a | Variant 2a | Variant 2a | NE |
Mutation of 23S rRNA | None | None | A2063G | A2063G | A2063G | NE |
Viral findings | Negative | Negative | Negative | Negative | Negative | Negative |
Antibiotic therapy | Ampicillin/sulbactam and clarithromycin | Meropenem and teicoplanin and clarithromycin | Meropenem and teicoplanin and clarithromycin | Meropenem and teicoplanin and ciprofloxacin | Ciprofloxacin | End of ciprofloxacin |
Supportive O2 therapy L·min−1 | 8 | 6 | 6 | 4 | NR | NR |